Verastem has dosed the first patient in a Phase 2 registration-directed trial of VS-7375 for previously treated advanced NSCLC with KRAS G12D mutations. The ora

BWB News TV • 2026-07-22 20:26 UTC • By Billy Odell Tucker-Robinson

Verastem has dosed the first patient in a Phase 2 registration-directed trial of VS-7375 for previously treated advanced NSCLC with KRAS G12D mutations. The oral KRAS G12D inhibitor targets a subgroup with limited treatment options.

Share this article

𝕏 X / Twitter Facebook LinkedIn WhatsApp

📚 More from Billy’s World

📰 Banking With Billy News All breaking financial news & market analysis 📚 Banking With Billy Books Deep-dive books on every financial story 💬 Join the Community discord.gg/VHxwmR5j4Y 🎥 Banking With Billy on YouTube Live streams & market commentary

Banking With Billy News Network — bankingwithbilly.com
Discord: discord.gg/VHxwmR5j4Y • YouTube: @BankingWithBilly